Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 3070-3079

  Bonneterre, Jacques ^a   Roché, Henri ^a   Kerbrat, Pierre ^a   Fumoleau, Pierre ^a   Goudier, Marie Josèphe ^a   Fargeot, Pierre ^a   Montcuquet, Philippe ^a   Clavère, Pierre ^a   Barats, Jean Claude ^a   Monnier, Alain ^a   Veyret, Corinne ^a   Datchary, Jean ^a   Van Praagh, Isabelle ^a   Chapelle Marcillac, Isabelle ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; FEC PROTOCOL;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG DOSE REGIMEN; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; HEART; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; LYMPH NODE METASTASIS; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEART; HEART FAILURE, CONGESTIVE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 4143076036     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.098     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
2. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
3. Praga C, Trave F, Petroccione A: Anthracycline-induced cardiotoxicity and its relevance in cancer treatment, in Nimmo WS, Tucker GT (eds): Clinical Measurement in Drug Evaluation. Boca Raton, FL, CRC Press. 1991, pp 131-142
4. Ryberg M, Nielsen D, Skovsgaard T, et al: Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-3508, 1998
5. Bonadonna G, Gianni L, Santoro A, et al: Drugs ten years later: Epirubicin. Ann Oncol 4:359-369, 1993
6. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
7. Italian Multicentre Breast Study with Epirubicin: Phase III randomised study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian Multicentre Trial. J Clin Oncol 6:976-982, 1988
8. Findlay BP, Walker-Dilks C: Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer: Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 2:140-146, 1998
9. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19:197-228, 1993
10. Ewer MS, Benjamin RS: Cardiac complications, in Bast RC, Gansler TS, Holland JF, et al (eds): Cancer Medicine (ed 5). Hamilton, Ontario, Canada, Decker, 2000, pp 2324-2339
11. Torti FM, Bristow MM, Lum BL, et al: Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 46:3722-3727, 1986
12. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
13. Snedecor GW, Cochran WG: Statistical Methods (ed 7). Ames, IA, Iowa State University Press, 1980
14. Duncan DB: P-tests and intervals for comparison suggested by the data. Biometrics 31:339-359, 1975
15. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998
16. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
17. Bristow MR, Mason JW, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168-175, 1978
18. Valagussa P, Zambetti M, Biasi S, et al: Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 5:209-216, 1994
19. Corn BW, Trock BJ, Goodman RL: Irradiation-related ischemic heart disease. J Clin Oncol 8:741-750, 1990
20. Shapiro CL, Hardenbergh P, Gelman R, et al: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493-3501, 1998
21. Dees EC, O'Reilly S, Goodman SN, et al: A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18:521-529, 2000
22. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
23. Alexander J, Dainiak N, Berger HJ: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979
24. Okumura H, Iuchi K, Yoshida T, et al: Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104:158-163, 2000
25. Cardinale D, Sandri MT, Martinoni A, et al: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710-715, 2002
26. Tjeerdsma G, Meinardi MT, van der Graaf WTA, et al: Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: Autonomic versus echocardiographic variables. Heart 81:419-423, 1999
27. Alderton PM, Gross J, Green MD: Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 52:194-201, 1992
28. Lenaz L, Page JA: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3:111-120, 1976
29. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 23:302-314, 1973
30. Lefrak EA, Pitha J, Rosenheim S, et al: Adriamycin (NSC-123127) cardiomyopathy. Cancer Chemother Rep 6:203-208, 1975
31. Minow RA, Benjamin RS, Gottlieb JA: Adriamycin cardiomyopathy: An overview with determination of risk factors. Cancer Chemother Rep 6:195-201, 1975
32. Praga C, Beretta G, Vigo PL, et al: Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 62:931-934, 1979
33. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879, 2003
34. Fumoleau P, Roché H, Kerbrat P, et al: Cardiac toxicity in operable breast cancer patients after adjuvant chemotherapy with epirubicin: 7-year analysis in 3577 patients of French Adjuvant Study Group trials. Breast Cancer Res Treat 76:5157, 2002 (abstr 640, suppl 1)
35. Chacon R, Galvez C, Romero Acuna L, et al: A clinical analysis of cardiac toxicity and other life-threatening toxicities in patients receiving anthracyclines as adjuvant treatment in breast cancer: Pronacam Cooperative Group. Proc Am Soc Clin Oncol 11:1992 (abstr 111)
36. Basser RL, Abraham R, Bik To L, et al: Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Ann Oncol 10:53-58, 1999
37. Levine MN, Pritchard KI, Bramwell VHC, et al: A randomized trial comparing CEF to CMF in premenopausal women with node-positive breast cancer: Update of NCIC CTG MA 5. Breast Cancer Res Treat 76:533, 2002 (abstr 17, suppl 1)
38. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001
39. Wils JA, Bliss JM, Coombes MG, et al: Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 17:1988-1998, 1999
40. Bonneterre J, Roché H, Kerbrat P, et al: French Adjuvant Study Group 05 trial (FEC 50 vs FEC 100): 10-year update of benefit/risk ratio after adjuvant chemotherapy in node-positive, early breast cancer patients. Proc Am Soc Clin Oncol 22:24. 2003 (abstr 93)